<DOC>
	<DOCNO>NCT00626548</DOCNO>
	<brief_summary>Enthuse M0 large phase III clinical trial study efficacy ZD4054 ( Zibotentan ) hormone resistant prostate cancer ( HRPC ) . This clinical trial test Endothelin A Receptor Antagonist ZD4054 ( Zibotentan ) improve progression-free survival overall survival background exist prostate cancer treatment . ZD4054 ( Zibotentan ) new type agent , think slow tumour growth spread block Endothelin receptor activity . This trial look effect ZD4054 ( Zibotentan ) hormone resistant prostate cancer ( HRPC ) patient rise PSA surgical medical castration evidence metastasis . All patient participate clinical trial receive exist prostate cancer treatment addition trial therapy . Half patient receive ZD4054 ( Zibotentan ) , half patient receive placebo addition standard prostate cancer therapy . By participate trial 50 % chance patient receive agent may slow progression tumour . No patient deprive standard prostate cancer therapy .</brief_summary>
	<brief_title>A Phase III Trial ZD4054 ( Zibotentan ) ( Endothelin A Antagonist ) Non-metastatic Hormone Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Endothelin A Receptor Antagonists</mesh_term>
	<criteria>Patients answer TRUE follow criterion may eligible participate study . Confirmed diagnosis prostate cancer ( adenocarcinoma prostate ) NOT spread part body ( metastasis ) . Patients lymph node involvement may eligible specify criterion meet . Increasing Prostate Specific Antigen ( PSA ) , collect within one year enrollment Currently receive treatment surgical medical castration Patients answer TRUE follow may NOT eligible participate study . Currently use opiate base pain killer cancer relate pain Previous treatment chemotherapy ( paclitaxel , docetaxel , mitoxantrone ) . Prior target cancer therapy permit receive previous clinical trial Suffering heart failure myocardial infarction within last 6 month A history epilepsy seizure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Hormone Resistant Prostate Cancer</keyword>
	<keyword>Endothelin A Receptor Antagonist</keyword>
	<keyword>Endothelin A</keyword>
	<keyword>Endothelin A antagonist</keyword>
</DOC>